Abnormal ERGs reversed to normal in patients treated with Jetrea

SEATTLE — Full-field electroretinograms in patients treated with ocriplasmin changed normally, and treated patients with abnormal ERGs reversed to normal by 2 years, according to a poster presented here.

The OASIS phase 3b clinical trial assessed long-term outcomes in patients with symptomatic vitreomacular adhesion (VMA), and this substudy evaluated “the relationship of ERG changes with anatomic and visual outcomes for up to 24 months after a single injection of ocriplasmin 0.125 mg,” Joseph I. Markoff, MD, said at the Association for Research in Vision and Ophthalmology meeting.

The prospective study included 61 patients with VMA. Of these patients, 40 were randomized to receive Jetrea (ocriplasmin, Thrombogenics) injections and 21 were randomized to the sham group.

“The prospective nature of the ERG substudy allowed for standardization and comparison of changes from baseline not possible with retrospective cases,” Markoff said.

ERGs were recorded from both eyes every 3 months for 2 years and were evaluated by a masked ERG expert, he said.

Researchers defined abnormal ERG changes as a change greater than 40% at baseline starting at day 7 or day 28.

Sixteen patients in the Jetrea group had abnormal ERG changes, but 13 of those resolved by 2 years.

The rate of VMA resolution was higher in patients with abnormal ERGs than in those with normal ERGs in the Jetrea group, Markoff said. – by Nhu Te

Reference:

Markoff J, et al. Evaluation of full-field electroretinogram changes after ocriplasmin injection in a substudy of symptomatic vitreomacular adhesion subjects from the OASIS trial. Presented at: ARVO; May 1-5, 2016; Seattle, Washington.

Disclosure: Markoff reports he is a consultant for Thrombogenics.